Precision medicine for metastatic renal cell carcinoma1

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 5-15

  Sonpavde, Guru ^a   Choueiri, Toni K ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarkers; Predictive; Prognostic; Renal cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER; VASCULOTROPIN A;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RISK; COMORBIDITY; DRUG MEGADOSE; HISTOLOGY; HISTOPATHOLOGY; HOST; HUMAN; IMAGING; KIDNEY CARCINOMA; KIDNEY METASTASIS; NONHUMAN; PATIENT PREFERENCE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); GENETICS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS;

BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890790069     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.07.010     Document Type: Review

References (112)

1. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
3. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
4. Motzer R.J., Hudes G., Wilding G., et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009, 7:28-33.
5. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
6. Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7:24-27.
7. Molina A.M., Feldman D.R., Voss M.H., et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011, 118:1868-1876.
8. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Proc European Society of Medical Oncology Congress LBA21, Vienna, Austria September 28-October 2. 2012.
9. Ravaud A, Barrios C, Anak O, et al. Randomized phase II study of first-line everolimus plus bevacizumab versus interferon alfa-2A plus bevacizumab in patients with metastatic renal cell carcinoma: RECORD-2. Proc European Society of Medical Oncology Congress Abstract 7830, Vienna, Austria September 28-October 2. 2012.
10. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
11. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
12. Gordan J.D., Lal P., Dondeti V.R., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
13. Dalgliesh G.L., Furge K., Greenman C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
14. Varela I., Tarpey P., Raine K., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
15. Kapur P., Pena-Llopis S., Christie A., et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013, 14:159-167.
16. Guo G., Gui Y., Gao S., et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2011, 44:17-19.
17. Vanharanta S., Buchta M., McWhinney S.R., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004, 74:153-159.
18. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
19. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
20. Huang D., Ding Y., Zhou M., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
21. Finke J., Ko J., Rini B., Rayman P., Ireland J., Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011, 11:856-861.
22. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343-2350.
23. Ooi A., Wong J.C., Petillo D., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20:511-523.
24. Vocke C.D., Yang Y., Pavlovich C.P., et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 2005, 97:931-935.
25. Menko F.H., van Steensel M.A., Giraud S., et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 2009, 10:1199-1206.
26. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
27. Heng D.Y., Xie W., Bjarnason G.A., et al. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study. J Clin Oncol 2010, 28(15 Suppl.). [abstr 4523].
28. Heng D.Y., Xie W., Regan M.M., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013, 14:141-148.
29. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
30. Patil S., Manola J., Elson P., et al. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 2012, 188:2095-2100.
31. Sonpavde G., Choueiri T.K. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer 2012, 107:1009-1016.
32. Al-Marrawi MY, Rini BI Harshman LC, et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013; Jan 9. [Epub ahead of print].
33. Heng D.Y., MacKenzie M., Vaishampayan U.N., et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol 2011, 29(Suppl. 7). [abstr 305].
34. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
35. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34. [discussion].
36. Reeves J.A., Spigel D., Daniel D.B., Friedman E.K., Burris H.A., Hainsworth J.D. Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trial. J Clin Oncol 2011, 29(Suppl.). [abstr 4659].
37. Motzer R.J., Escudier B., Tomczak P., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013, 14:552-562.
38. Escudier B, Hutson T, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Proc European Society of Medical Oncology Congress Abstract LBA22, Vienna, Austria September 28-October 2. 2012.
39. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
40. Harzstark A.L., Halabi S., Stadler W.M., et al. Hypertension is associated with clinical outcome for patients(pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Genitourin Cancer Symp 2010, [abstr 351].
41. Rini B.I., Schiller J.H., Fruehauf J.P., et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011, 17:3841-3849.
42. Hurwitz H.I., Douglas P.S., Middleton J.P., et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013, 18:273-280.
43. Rini B.I., Gruenwald V., Fishman M.N., et al. Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): unblinded results from a randomized phase II study. J Clin Oncol 2013, 31(Suppl. 6). [abstr LBA349].
44. Michaelson M.D., Cohen D., Li S., et al. Hand-foot syndrome as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 2011, 29(Suppl. 7). [abstract 320].
45. Pinto F., Pereira A., Formiga M., et al. Association of hypothyroidism with improved outcomes in first-line treatment of renal cell carcinoma with sunitinib. J Clin Oncol 2012, 30(Suppl. 5). [abstr 466].
46. Dabydeen D.A., Jagannathan J., Ramaiya N.H., et al. Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome. J Clin Oncol 2011, 29(Suppl.). [abstr e15176].
47. Lee C.K., Marschner I., Simes J., et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012 Jun 1, 18(11):3188-3196.
48. Escudier B.J., Porta C., Bono P., et al. Patient preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma-PISCES study. J Clin Oncol 2012, 30(Suppl.). [abstr CRA4502].
49. Upton M.P., Parker R.A., Youmans A., McDermott D.F., Atkins M.B. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005, 28:488-495.
50. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
51. Choueiri T.K., Regan M.M., Rosenberg J.E., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106:772-778.
52. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127-131.
53. Lee J.L., Ahn J.H., Lim H.Y., et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012 Aug, 23(8):2108-2114.
54. Golshayan A.R., George S., Heng D.Y., et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009, 27:235-241.
55. Dutcher J.P., de Souza P., McDermott D., et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009, 26:202-209.
56. Motzer R.J., Barrios C., Kim T.M., et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013, 31(Suppl.). [abstr 4504].
57. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-3721.
58. McDermott D.F., Ghebremichael M., Signoretti S., Margolin K.A., Clark J., Sosman J.A., et al. The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28(15 Suppl.). [abstr 4514].
59. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 98:2566-2575.
60. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865. [discussion 5-6].
61. Choueiri T.K., Cheng S., Qu A.Q., Pastorek J., Atkins M.B., Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012 Nov 7, [Epub ahead of print].
62. Patel P.H., Chadalavada R., Ishill N.M., et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008, 26(15 Suppl.). [abstr 5008].
63. Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385.
64. Figlin R.A., de Souza P., McDermott D., et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009, 115:3651-3660.
65. Kucejova B., Pena-Llopis S., Yamasaki T., et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011, 9:1255-1265.
66. Abou Youssif T., Fahmy M.A., Koumakpayi I.H., et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2010, 117:290-300.
67. Di Nicolantonio F., Arena S., Tabernero J., et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866.
68. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008, 283:34495-34499.
69. Voss MH, Hakimi AA, Pham CG, Brannon AR, Scott S, Takeda S,et al. Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC. Kidney Cancer Association meeting 2012, Chicago, IL.
70. Pena C., Lathia C., Shan M., Escudier B., Bukowski R.M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010, 16:4853-4863.
71. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
72. Zurita A.J., Jonasch E., Wang X., et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011, 23:46-52.
73. Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32.
74. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
75. Tran H.T., Liu Y., Zurita A.J., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, 13:827-837.
76. Bhatt R.S., Zurita A.J., O'Neill A., et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer 2011, 105:112-117.
77. Gruenwald V., Beutel G., Schuch-Jantsch S., et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC cancer 2010, 10:695.
78. Armstrong A.J., George D.J., Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012, 30(27):3402-3407.
79. Xu C.F., Bing N.X., Ball H.A., et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29:2557-2564.
80. Xu C.F., Johnson T., Choueiri T.K., Deen K.C., Xue Z., Spraggs C.F., et al. Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study). J Clin Oncol 2013, 31(Suppl.). [abstr 4519].
81. Kim J.J., Vaziri S.A., Rini B.I., et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118(7):1946-1954.
82. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
83. Escudier B., Loomis A.K., Kaprin A., et al. Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the Phase 3 trial of axitinib versus sorafenib (AXIS trial) cell carcinoma (mRCC) in the Phase 3 trial of axitinib versus sorafenib (AXIS trial). Eur J Cancer 2011, 47(Suppl. 1):S7505. [Abstract 7103].
84. Schutz F.A., Pomerantz M.M., Gray K.P., et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 2012, 14:81-87.
85. Choueiri T.K., Vaishampayan U., Rosenberg J.E., et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 31:181-186.
86. Jain L., Sissung T.M., Danesi R., et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010, 29:95.
87. Garcia-Donas J., Esteban E., Leandro-Garcia L.J., et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, 12:1143-1150.
88. van der Veldt A.A., Eechoute K., Gelderblom H., et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17:620-629.
89. European Collaborative Project EuroTARGET. http://www.eurotargetproject.eu.
90. Katani I., Avril N.E., Bomanji J., et al. Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011, 17(18):6021-6028.
91. Hahn O.M., Yang C., Medved M., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
92. Lassau N., Koscielny S., Albiges L., et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010, 16:1216-1225.
93. Ma W.W., Jacene H., Song D., et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009, 27:2697-2704.
94. Chen J.L., Appelbaum D.E., Kocherginsky Rathmell K., McDermott D.F., Stadler W.M. FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer. J Clin Oncol 2011, 29(Suppl.). [abstr e15047].
95. Smith A.D., Shah S.N., Rini B.I., Lieber M.L., Remer E.M. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am J Roentgenol 2010, 194:1470-1478.
96. Krajewski K.M., Guo M., Van den Abbeele A.D., et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011, 59:856-862.
97. Thiam R., Fournier L.S., Trinquart L., et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010, 21:936-941.
98. Nathan P.D., Vinayan A., Stott D., Juttla J., Goh V.C.T. response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010, 9:15-19.
99. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., Haanen J.B., Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010, 102:803-809.
100. Pedrosa I., Alsop D.C., Rofsky N.M. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 2009, 115:2334-2345.
101. de Bazelaire C., Alsop D.C., George D., et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008, 14:5548-5554.
102. Sudarshan S., Karam J.A., Brugarolas J., et al. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol 2012, 63:244-251.
103. Di Napoli A., Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009, 115:2290-2297.
104. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
105. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
106. Cho D.C., Sosman J.A., Sznol M., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma. J Clin Oncol 2013, 31(Suppl.). [abstr 4505].
107. Mandrekar S.J., Sargent D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009, 27:4027-4034.
108. Jonasch E., Corn P.G., Pagliaro L.C., et al. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol 2013, 31(Suppl.). [abstr 4517].
109. Jonasch E., Tsavachdidou D., Wood C.G., et al. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(Suppl.):15s. [abstr 5004].
110. Sivanand S., Pena-Llopis S., Zhao H., et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012, 4:137ra75.
111. Choueiri T.K., Cheng S., Qu A.Q., Pastorek J., Atkins M.B., Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012; Nov 7, [Epub ahead of print].
112. Hutson T.E.D.I., Machiels J.H., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26:5046.